Small molecule · Inhibitor of hematopoietic progenitor kinase 1 (MAP4K1) · developed by BeOne Medicines
BGB-26808 is an orally bioavailable inhibitor of hematopoietic progenitor kinase 1 (HPK1, encoded by MAP4K1), a negative regulator of T-cell and B-cell receptor signaling. By inhibiting HPK1, it is intended to restore T-cell receptor signaling and effector T-cell activity against tumors. It is being studied in advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid TumorSolid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →